Cephalomannine

Cephalomannine is a Paclitaxel (HY-B0015) alkaloidal analog that can be isolated from most Cephalotaxus species. Cephalomannine is an orally active anti-tumor agent and can be used as a chemotherapy agent for cancer research^[1][2][3][4]. In Vitro:Cephalomannine significantly inhibits the proliferation of H460, A549 and H1299 cells under normal oxygen conditions, with IC₅₀ values of 0.18, 0.20 and 0.37 μM, respectively. Cephalomannine shows obvious inhibitory effect on cell viability under hypoxia^[3].
Cephalomannine (0, 0.025, 0.05, 0.1 μM; 0, 12, 24h) inhibiting the interaction of APEX1/HIF-1α can also significantly inhibit the cell viability, ROS production, intracellular pH, migration of hypoxic lung cancer cells, and angiogenesis of hypoxic human umbilical vein endothelial cells (HUVECs)^[3].
Cephalomannine dose-dependently inhibits UBE2S expression and thus suppresses prostate cancer (PCa) growth and metastasis^[4].
In Vivo:Cephalomannine (0.4 mg/kg, intraperitoneal injection, 10 days) could significantly inhibit the growth of lung cancer cells in nude mice xenograft model, with no obvious side effects^[3].
Cephalomannine can interrupt the interaction between APEX1 and HIF-1α by competitive binding with APEX1^[3].